显示样式:     当前分类: 医药    当前期刊: Nature Reviews Drug Discovery    加入关注    导出
我的关注
我的收藏
您暂时未登录!
登录
  • Neurodegenerative disease: DLK zips across neurodegeneration
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    M. Teresa Villanueva

    Neurodegenerative disease: DLK zips across neurodegeneration Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.180

    更新日期:2017-09-22
  • RNA-based therapeutics: Increasing efficacy
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Sarah Crunkhorn

    RNA-based therapeutics: Increasing efficacy Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.182

    更新日期:2017-09-22
  • Infectious disease: Blocking malaria transmission
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Sarah Crunkhorn

    Infectious disease: Blocking malaria transmission Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.184

    更新日期:2017-09-22
  • Synthetic lethality screens point the way to new cancer drug targets
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    Synthetic lethality screens point the way to new cancer drug targets Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.190

    更新日期:2017-09-22
  • Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Stephen P. Arnerić, Jesse M. Cedarbaum, Sean Khozin, Spyros Papapetropoulos, Derek L. Hill, Michael Ropacki, Jane Rhodes, Penny A. Dacks, Lynn D. Hudson, Mark Forrest Gordon, Volker D. Kern, Klaus Romero, George Vradenburg, Rhoda Au, Daniel R. Karlin, Maurizio F. Facheris, Cheryl J. Fitzer-Attas, Ottavio V. Vitolo, Jian Wang, Bradley M. Miller, Jeffrey A. Kaye

    Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.153

    更新日期:2017-09-22
  • Autoimmune disease: LKB1 helps Treg cells battle exhaustion
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Megan Cully

    Autoimmune disease: LKB1 helps Treg cells battle exhaustion Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.188

    更新日期:2017-09-22
  • Neurological disorders: Reversing Rett syndrome
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Sarah Crunkhorn

    Neurological disorders: Reversing Rett syndrome Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.181

    更新日期:2017-09-22
  • CNS injury: Promoting neural repair
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Sarah Crunkhorn

    CNS injury: Promoting neural repair Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.183

    更新日期:2017-09-22
  • Market watch: Upcoming market catalysts in Q4 2017
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Gregory Pak

    Market watch: Upcoming market catalysts in Q4 2017 Nature Reviews Drug Discovery, Published online: 15 September 2017; doi:10.1038/nrd.2017.185

    更新日期:2017-09-18
  • The human microbiome: opportunity or hype?
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-15
    Pedro M. Valencia, Magali Richard, Jesse Brock, Elsy Boglioli

    The human microbiome: opportunity or hype? Nature Reviews Drug Discovery, Published online: 15 September 2017; doi:10.1038/nrd.2017.154 This article discusses investment in microbiome-based therapeutic approaches and key questions for the field related to the underlying science, clinical development, regulation and business models.

    更新日期:2017-09-18
  • Synthetic lethality screens point the way to new cancer drug targets
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    Synthetic lethality screens point the way to new cancer drug targets Nature Reviews Drug Discovery, Published online: 15 September 2017; doi:10.1038/nrd.2017.189

    更新日期:2017-09-18
  • Patent watch: The evolving intellectual property landscape for pruritus therapies
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Benjamin Leung, Drew Lowery

    Patent watch: The evolving intellectual property landscape for pruritus therapies Nature Reviews Drug Discovery, Published online: 8 September 2017; doi:10.1038/nrd.2017.161

    更新日期:2017-09-09
  • Cancer: Ironing it out
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Ulrike Harjes

    Cancer: Ironing it out Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.168

    更新日期:2017-09-07
  • Nigel Blackburn
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 

    Nigel Blackburn Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.172 Nigel Blackburn, Director of drug development at CRUK, discusses the charity's changing approach to bolstering the cancer drug pipeline.

    更新日期:2017-09-07
  • FDA approves first-in-class cancer metabolism drug
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    FDA approves first-in-class cancer metabolism drug Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.174

    更新日期:2017-09-07
  • FDA rejects first-in-class osteoporosis drug
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    FDA rejects first-in-class osteoporosis drug Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.176

    更新日期:2017-09-07
  • Flexibility in the FDA approach to orphan drug development
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Nina L. Hunter, Gayatri R. Rao, Rachel E. Sherman

    Flexibility in the FDA approach to orphan drug development Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.151 Scientific advances, in combination with government incentives and commercial opportunity, have fuelled strong investment in orphan drugs, resulting in many innovative therapies. Here, we discuss the approach of the FDA to a range of issues that remain crucial to maintaining this momentum, such as the use of the totality of evidence in evaluating orphan drugs.

    更新日期:2017-09-07
  • Synthetic lethality screens point the way to new cancer drug targets
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    Synthetic lethality screens point the way to new cancer drug targets Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.165 A resurgence in synthetic lethality screening, enabled by CRISPR gene editing, is unlocking targeted drugs for patients with cancerous loss-of-function mutations.

    更新日期:2017-09-07
  • Biotechnology: CRISPR–Cas becoming more human
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Kim Baumann

    Biotechnology: CRISPR–Cas becoming more human Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.167

    更新日期:2017-09-07
  • Deal watch: IL-2 focus switches to stimulating Tregs
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Megan Cully

    Deal watch: IL-2 focus switches to stimulating Tregs Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.171

    更新日期:2017-09-07
  • NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-08-04
    Elliott M. Antman, Paul E. Di Corleto, Mason W. Freeman, Tomas Ganz, David E. Golan, Roger Kitterman, Joseph Loscalzo, Mark Low, Erin McKenna, Alan C. O'Connor, Michael Palazzolo, John Parrish, Ofer Reizes, Robert S. Ross, Cheryl Vaughan, D. Geoffrey Vince, Lesley Watts, for the NIH Centers for Accelerated Innovations

    Commercializing innovations in academic environments is notoriously challenging. Here, we describe the progress of the NIH Centers for Accelerated Innovations program — initiated in 2013 to address these challenges — which we believe could help set a new standard for the early-stage commercialization of biomedical innovations in academic environments.

    更新日期:2017-09-06
  • The multiple sclerosis market
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-06-23
    Anders Westad, Aditya Venugopal, Eric Snyder

    This article discusses the impact of new drugs on the market for multiple sclerosis, including the recently approved immunomodulatory drug ocrelizumab and drugs in development such as sphingosine 1-phosphate receptor modulators and neurorestorative agents.

    更新日期:2017-09-06
  • Pulling away from the pack in drug launches
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-08-18
    Nicholas Donoghoe, Jon Duane, Jin Kim, George Xu

    This analysis of US drug launches from the past decade indicates that commercial success has become more difficult to achieve, owing to factors such as increased competition, greater challenges in achieving therapeutic differentiation and payer pressures.

    更新日期:2017-09-06
  • Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-14
    Catherine J. Hutchings, Markus Koglin, William C. Olson, Fiona H. Marshall

    G-protein-coupled receptors (GPCRs) are activated by a diverse range of ligands, from large proteins and proteases to small peptides, metabolites, neurotransmitters and ions. They are expressed on all cells in the body and have key roles in physiology and homeostasis. As such, GPCRs are one of the most important target classes for therapeutic drug discovery. The development of drugs targeting GPCRs has therapeutic value across a wide range of diseases, including cancer, immune and inflammatory disorders as well as neurological and metabolic diseases. The progress made by targeting GPCRs with antibody-based therapeutics, as well as technical hurdles to overcome, are presented and discussed in this Review. Antibody therapeutics targeting C-C chemokine receptor type 4 (CCR4), CCR5 and calcitonin gene-related peptide (CGRP) are used as illustrative clinical case studies.

    更新日期:2017-09-06
  • Heart regeneration and repair after myocardial infarction: translational opportunities for novel therapeutics
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-21
    Thomas J. Cahill, Robin P. Choudhury, Paul R. Riley

    Current therapies for heart failure after myocardial infarction are limited and non-curative. Although regenerative approaches are receiving significant attention, clinical efforts that involve transplantation of presumed stem and progenitor cells have largely failed to deliver. Recent studies of endogenous heart regeneration in model organisms, such as zebrafish and neonatal mice, are yielding mechanistic insights into the roles of cardiomyocyte proliferation, resident stem cell niches, neovascularization, the immune system and the extracellular matrix. These findings have revealed novel pathways that could be therapeutically targeted to stimulate repair following myocardial infarction and have provided lessons to guide future efforts towards heart regeneration through cellular reprogramming or cardiomyocyte transplantation.

    更新日期:2017-09-06
  • Senescent cells: an emerging target for diseases of ageing
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-21
    Bennett G. Childs, Martina Gluscevic, Darren J. Baker, Remi-Martin Laberge, Dan Marquess, Jamie Dananberg, Jan M. van Deursen

    Chronological age represents the single greatest risk factor for human disease. One plausible explanation for this correlation is that mechanisms that drive ageing might also promote age-related diseases. Cellular senescence, which is a permanent state of cell cycle arrest induced by cellular stress, has recently emerged as a fundamental ageing mechanism that also contributes to diseases of late life, including cancer, atherosclerosis and osteoarthritis. Therapeutic strategies that safely interfere with the detrimental effects of cellular senescence, such as the selective elimination of senescent cells (SNCs) or the disruption of the SNC secretome, are gaining significant attention, with several programmes now nearing human clinical studies.

    更新日期:2017-09-06
  • Bridging the translational innovation gap through good biomarker practice
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-04-28
    Alain J. van Gool, Florence Bietrix, Eric Caldenhoven, Kurt Zatloukal, Andreas Scherer, Jan-Eric Litton, Gerrit Meijer, Niklas Blomberg, Andy Smith, Barend Mons, Jaap Heringa, Wim-Jan Koot, Martin J. Smit, Marian Hajduch, Ton Rijnders, Anton Ussi

    Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way to developing and sharing best practices for biomarker validation.

    更新日期:2017-09-04
  • FDA OKs first in vitro route to expanded approval
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Katie Kingwell

    In vitro data can be used to accelerate the approval of drugs that target specific disease-causing mutations for additional subpopulations of patients with rare diseases such as cystic fibrosis.

    更新日期:2017-09-04
  • Synthetic lethality screens point the way to new cancer drug targets
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Asher Mullard

    A resurgence in synthetic lethality screening, enabled by CRISPR gene editing, is unlocking targeted drugs for patients with cancerous loss-of-function mutations.

    更新日期:2017-09-04
  • FDA rejects first-in-class osteoporosis drug
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Asher Mullard

    The FDA rejected Amgen's and UCB's romosozumab, an anti-sclerostin monoclonal antibody that the firms are developing for the treatment of osteoporosis. The rejection followed on the heels of a cardiovascular safety signal that the companies reported in May. Amgen and UCB are now working

    更新日期:2017-09-04
  • Diabetes drug shows promise in Parkinson disease
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Asher Mullard

    There are no approved disease-modifying drugs for Parkinson disease, a neurodegenerative condition that affects 2–3% of people aged ≥65 years. Accumulating evidence suggests that GLP1 receptor agonists — incretin mimetics that researchers first developed for the treatment of diabetes — may have neuroprotective properties. A

    更新日期:2017-09-04
  • FDA approves first-in-class cancer metabolism drug
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Asher Mullard

    The FDA approved Agios' and Celgene's enasidenib for acute myeloid leukaemia (AML), validating metabolism-modulating drugs as a means of killing cancer cells.Enasidenib (formerly AG-221) is a first-in-class inhibitor of mutated isocitrate dehydrogenase 2 (IDH2). The IDH enzymes normally metabolize isocitrate into α-ketoglutarate. When

    更新日期:2017-09-04
  • Deal watch: IL-2 focus switches to stimulating Tregs
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Megan Cully

    Recombinant interleukin-2 (IL-2) has been used since the early 1990s for the treatment of renal cell carcinoma and melanoma, as high-dose IL-2 has immune-stimulating properties. A spate of deals in 2017 — including Eli Lilly's acquisition of co-development rights to Nektar's NKTR-358, the acquisition

    更新日期:2017-09-04
  • Regulatory watch: Structural and procedural characteristics of international regulatory authorities
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-08-11
    Anand B. Jain, Annette Mollet, Thomas D. Szucs

    Drug reviewers in regulatory authorities (health authorities) around the world have the responsibility of evaluating safety, effectiveness and quality control data for a new drug before it is approved for marketing. The regulatory requirements, structure and processes of various regulatory authorities are different, making it

    更新日期:2017-09-04
  • Nigel Blackburn
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01

    In 2007, the charity Cancer Research UK (CRUK) launched its Clinical Development Partnerships (CDP) initiative to run trials of deprioritized anticancer candidates that still offered glimmers of promise. 10 years on, these reprioritization efforts have yielded mixed results. Despite generating some promising clinical data, none of their biopharma partners has as yet fully reprioritized any candidates. There is still hope for these drugs, although likely with new sponsors. In the case of an Aurora kinase inhibitor that was initially discovered by GlaxoSmithKline (GSK), for example, Nemucore has since licensed CRUK's data and further development rights. Now, however, smaller biotech firms are increasingly turning to the CDP for help with clinical trials of lead drug candidates. Nigel Blackburn, CRUK's Director of drug development, discusses the CDP's changing strategy with Asher Mullard

    更新日期:2017-09-04
  • What is the right amount to spend on biopharma R&D?
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-07
    Michael S. Ringel

    This analysis investigates whether some companies may be negatively affecting their overall commercial success by aiming to maintain steady earnings per share growth and/or a target ratio of R&D spending to sales.

    更新日期:2017-09-04
  • Antibacterial agents: New routes to tuberculosis treatment
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-08-11
    Sarah Crunkhorn

    Treatment of drug-resistant strains of Mycobacterium tuberculosis is lengthy, involving the use of costly and less effective second-line drugs that exhibit substantial side effects. Two new papers now report the identification of novel agents that inhibit previously untargeted essential M. tuberculosis enzymes and

    更新日期:2017-09-04
  • Cancer immunotherapy: Searching in the immune checkpoint black box
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-08-11
    M. Teresa Villanueva

    Checkpoint blockade through inhibition of programmed cell death protein 1 (PD1), which enables tumours to evade the immune system, has radically changed the treatment and prognosis of many cancers, especially melanoma. However, a majority of patients do not respond to PD1 inhibition, and great effort

    更新日期:2017-09-04
  • Anticancer agents: Fighting resistance
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-08-11
    CrunkhornSarah

    RAF–MEK–ERK pathway inhibitors are used to treat cancers exhibiting BRAFV600E mutations, but drug resistance commonly develops. Here, analysis of patient-derived xenograft (PDX) of BRAFV600E-mutant cancers and single-cell DNA sequencing showed that following drug treatment, parallel evolutionary tracts enable the selection and

    更新日期:2017-09-04
  • Biotechnology: CRISPR–Cas becoming more human
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Kim Baumann

    In the past few years, the CRISPR–Cas technology has been developed to precisely edit genomic DNA; so far, these approaches have been used mainly in cultured cells or in animal embryo models, but only a few studies have reported their use in human embryos. Ma

    更新日期:2017-09-04
  • Inflammatory diseases: An IL-9 solution to inflammation resolution
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-08-18
    Megan Cully

    Drugs for inflammation-driven diseases, such as rheumatoid arthritis, often aim to reduce the severity of the inflammatory response. Rauber et al. suggest an alternative strategy: promoting the resolution of inflammation. They found that IL-9 is needed for regulatory T (Treg) cells, which

    更新日期:2017-09-04
  • Systems medicine: Understanding wellness and disease
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-08-11
    CrunkhornSarah

    Systems medicine aims to understand the basis of wellness and disease. Here, Price et al. report findings from the Pioneer 100 Wellness Project, a collection of data from 108 individuals over 9 months - including whole genome sequences, clinical tests, metabolomes, proteomes, microbiomes and

    更新日期:2017-09-04
  • Immunotherapy: CAR T cells in glioblastoma
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-08-11
    CrunkhornSarah

    Chimeric antigen receptor-modified T (CAR T) cells have shown efficacy in leukaemia and lymphoma. Now, O'Rourke et al. report on the first clinical trial of CAR T cells targeted to the epidermal growth factor receptor variant III (EGFRvIII) in 10 patients with recurrent glioblastoma.

    更新日期:2017-09-04
  • Cancer: Inhibiting ROCK in neuroblastoma
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-08-11
    CrunkhornSarah

    Neuroblastoma is a childhood tumour originating from the neural crest, for which treatment options are limited. Dyberg et al. report a high frequency of mutations in genes associated with RHO–RAC signalling in human neuroblastoma samples. Increased expression of the downstream RHO-activating kinase ROCK2 was

    更新日期:2017-09-04
  • The antifungal pipeline: a reality check
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-05-12
    John R. Perfect

    Invasive fungal infections continue to appear in record numbers as the immunocompromised population of the world increases, owing partially to the increased number of individuals who are infected with HIV and partially to the successful treatment of serious underlying diseases. The effectiveness of current antifungal therapies — polyenes, flucytosine, azoles and echinocandins (as monotherapies or in combinations for prophylaxis, or as empiric, pre-emptive or specific therapies) — in the management of these infections has plateaued. Although these drugs are clinically useful, they have several limitations, such as off-target toxicity, and drug-resistant fungi are now emerging. New antifungals are therefore needed. In this Review, I discuss the robust and dynamic antifungal pipeline, including results from preclinical academic efforts through to pharmaceutical industry products, and describe the targets, strategies, compounds and potential outcomes.

    更新日期:2017-09-04
  • Cancer: Ironing it out
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Ulrike Harjes

    Cancer cells with mesenchymal-like properties are more likely to become resistant to a wide range of therapies. A new study suggests that this mesenchymal-like state of cancer cells is vulnerable to inhibition of the lipid peroxidase pathway, leading to an iron-dependent form of cell death,

    更新日期:2017-09-04
  • Remyelination therapies: a new direction and challenge in multiple sclerosis
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-07
    Jason R. Plemel, Wei-Qiao Liu, V. Wee Yong

    Multiple sclerosis is characterized by inflammatory activity that results in destruction of the myelin sheaths that enwrap axons. The currently available medications for multiple sclerosis are predominantly immune-modulating and do not directly promote repair. White matter regeneration, or remyelination, is a new and exciting potential approach to treating multiple sclerosis, as remyelination repairs the damaged regions of the central nervous system. A wealth of new strategies in animal models that promote remyelination, including the repopulation of oligodendrocytes that produce myelin, has led to several clinical trials to test new reparative therapies. In this Review, we highlight the biology of, and obstacles to, remyelination. We address new strategies to improve remyelination in preclinical models, highlight the therapies that are currently undergoing clinical trials and discuss the challenges of objectively measuring remyelination in trials of repair in multiple sclerosis.

    更新日期:2017-09-04
  • Therapeutic targeting of the angiopoietin–TIE pathway
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-05-19
    Pipsa Saharinen, Lauri Eklund, Kari Alitalo

    The endothelial angiopoietin (ANG)–TIE growth factor receptor pathway regulates vascular permeability and pathological vascular remodelling during inflammation, tumour angiogenesis and metastasis. Drugs that target the ANG–TIE pathway are in clinical development for oncological and ophthalmological applications. The aim is to complement current vascular endothelial growth factor (VEGF)-based anti-angiogenic therapies in cancer, wet age-related macular degeneration and macular oedema. The unique function of the ANG–TIE pathway in vascular stabilization also renders this pathway an attractive target in sepsis, organ transplantation, atherosclerosis and vascular complications of diabetes. This Review covers key aspects of the function of the ANG–TIE pathway in vascular disease and describes the recent development of novel therapeutics that target this pathway.

    更新日期:2017-09-04
  • Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Catherine J. Hutchings, Markus Koglin, William C. Olson, Fiona H. Marshall

    Nature Reviews Drug Discovery16 (2017)In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version.

    更新日期:2017-09-04
  • Combination products: modernizing the regulatory paradigm
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-05-12
    Nina L. Hunter, Rachel E. Sherman

    New opportunities to develop innovative — and often complex — products that combine drugs, devices and/or biological components are rapidly emerging, raising questions about how such products should be regulated. Here, we discuss the ongoing efforts of the FDA to develop a modern, transparent, flexible

    更新日期:2017-08-02
  • Calls grow to tap the gold mine of human genetic knockouts
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-31
    Asher Mullard

    A Human Knockout Project would systematically search for loss-of-function genetic mutations in humans to help uncover new drug targets.

    更新日期:2017-08-02
  • FDA approvals for the first 6 months of 2017
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-31
    Asher Mullard

    The US FDA approved 23 new drugs in the first 6 months of 2017 (Table 1). This is more than the agency approved in the entirety of 2016, a lacklustre year with only 22 approvals (Nat. Rev. Drug Discov.16, 73–76;

    更新日期:2017-08-02
  • FDA approves first new sickle cell drug in 20 years
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-31
    Asher Mullard

    The US FDA approved Emmaus Medical's L-glutamine for sickle cell anaemia, providing the first new drug for these patients in 20 years.Emmaus's drug is an oral, pharmaceutical-grade amino acid. The mechanism of action of the drug is not understood, but it is thought

    更新日期:2017-08-02
  • New cancer vaccines show clinical promise
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-31
    Asher Mullard

    Personalized cancer vaccines can help to stave off melanoma, suggested two phase I clinical trials published in Nature. The findings buoyed an emerging field that is using neoantigens — antigens that are unique to each patient's cancer — to prime the immune system to

    更新日期:2017-08-02
  • Market watch: Strategies for biosimilars in emerging markets
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-07
    Ajay Gautam

    Biologic drugs remain inaccessible to most patients in emerging markets. Biosimilars represent a compelling proposition for patient affordability and access, and attractive value for governments in many of these countries. However, quality concerns, technology hurdles, lack of robust regulatory frameworks, and development timelines and costs

    更新日期:2017-08-02
  • Patent watch: Supreme Court decision favours biosimilars
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-31
    Courtenay C. Brinckerhoff

    On June 12, 2017, the US Supreme Court issued a unanimous decision in Sandoz Inc. v. Amgen Inc. (No. 15-1039), providing its first interpretation of the patent dispute resolution provisions of the Biologics Price Competition and Innovation Act (BPCIA). The Court essentially held that

    更新日期:2017-08-02
  • Joshua Gordon
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-31

    In September 2016, Joshua Gordon joined the NIH as Director of the National Institute of Mental Health (NIMH). For Gordon, who was previously a psychiatrist and neuroscientist at Columbia University Medical Center, this role presented a once-in-a-lifetime opportunity to oversee a US$1.5 billion budget and shape the future of mental health research. When he started, he said his first order of business would be to listen and learn. One year on, he has heard a lot about the institute's classification of mental illnesses for research purposes (known as RDoC), the appropriate balance between basic and clinical research, and the challenges of using genetics to understand psychiatric disease, he told Asher Mullard.

    更新日期:2017-08-02
  • Colorectal cancer drugs market
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-05-19
    Sorcha Cassidy, Basharut A. Syed

    The market for colorectal cancer therapies, which is currently dominated by drugs targeting vascular endothelial growth factor and epidermal growth factor receptor, is poised for change with the anticipated entry of immunotherapies and other targeted drugs.

    更新日期:2017-08-02
  • Infectious diseases: Decrypting Cryptosporidium
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-31
    M. Teresa Villanueva

    Infections that cause diarrhoea — such as cryptosporidiosis, caused by the protozoan parasites Cryptosporidium hominis and Cryptosporidium parvum — are responsible for nearly a million deaths every year, mostly among children in low-income countries as well as immunodeficient patients. Unfortunately, drug development against

    更新日期:2017-08-02
  • Muscle disorders: FGF19 reduces muscle wasting
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-07-21
    Megan Cully

    Muscle wasting can result from numerous conditions, including obesity, sarcopenia and cachexia, as well as long-term glucocorticoid treatment for inflammatory diseases. Writing in Nature Medicine, Benoit and colleagues demonstrate that fibroblast growth factor 19 (FGF19) can reduce muscle wasting in mice, likely though effects

    更新日期:2017-08-02
Some contents have been Reproduced with permission of the American Chemical Society.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
所有期刊列表A-Z